Innova Captab credit ratios

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024

344	344	338	245
299	299	270	158
0.32×	0.32×	0.35×	0.29×
0.28×	0.28×	0.28×	0.19×
1.41×	1.41×	1.82×	1.59×
1.15×	1.23×	1.45×	1.03×
11.70×	11.70×	67.10×	6.45×
24.1%	24.1%	26.1%	22.8%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

INNOVACAP₹1,051.10

Innova Captab Limited

· Pharma & Health

₹ CrorePeersMOREPENLAB IOLCP FDC SENORES SANOFI ORCHPHARMA GUJTHEM RPGLIFEMcap ₹6,015 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Total Debt	245.1	338.1	343.7	343.7
Net Debt	158.4	270.0	298.5	298.5
Total Debt/Equity	0.29	0.35	0.32	0.32
Net Debt/Equity	0.19	0.28	0.28	0.28
Total Debt/EBITDA	1.59	1.82	1.41	1.41
Net Debt/EBITDA	1.03	1.45	1.23	1.15
Interest Coverage (EBIT/Interest)	6.45	67.10	11.70	11.70
Total Debt/Total Capital %	22.78	26.06	24.12	24.12

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.